Biography
Dr Elif Dokmeci received Medical Doctor degree from Marmara University School of Medicine in 1995, Istanbul Turkey. She completed Pediatric Residency at LSU Shreveport, LA in 2003. Following her residency, she completed dual Fellowship programs at Yale University School of Medicine, New Haven CT. She finished Pediatric Pulmonology in 2006 and Allergy and Immunology in 2008.
Personal Statement
Before joining to UNM in July of 2016, she served as a Clinical Director of Pediatric Allergy and Immunology Section and Director of Pediatric Primary Immunodeficiency Program at Yale University, New Haven CT. She has a longstanding commitment to allergy and clinical immunology programs with a track record of building Pediatric Allergy and Immunodeficiency Centers in the past. She was chosen one of the leading expert Immunologist by Jeffrey Modell Diagnostic Center for Primary Immunodeficiency Diseases and Primary Immunodeficiency Foundation (IDF). She is the Medical Director of New Mexico Newborn Screening Program for Severe Combined Immunodeficiency (SCID) and Section Chief of Pediatric Allergy and Immunology at UNM, is the leading institution in the state for primary immunodeficiency diagnosis and treatment. She has multiple publications and presentations in National and International Meetings. She has been actively teaching at Medical School and Residency/Fellowship programs. She has done basic science research on immune mechanisms of asthma and allergic skin disorders at Yale University. She currently leads Pediatric Atopic Dermatitis clinical research trial at UNM. Dr. Dokmeci holds several national allergy and immunology committee appointments for the American Academy of Allergy, Asthma and Immunology and Clinical Immunology Society. Dr Dokmeci is currently President of New Mexico Allergy Society.
Areas of Specialty
Her clinical interests are Primary Immunodeficiency Diseases, Food Allergies, Hypersensitivity, Atopic Dermatitis, Immune Dysregulation Syndromes. Her research interests are immunodeficiency disorders, molecular and cellular mechanisms of allergic disorders.
Certifications
Pediatrics Pediatric Pulmonology Allergy and Clinical Immunology
Achievements & Awards
• Primary Investigator Atopic Dermatitis Clinical Trials, Abbvie Project Period: 2018-current Phase 3, Randomized, Placebo control, Double Blind Study to evaluate Upadacitinib in Pediatric Subjects with Moderate to Severe Atopic Dermatitis • Co Primary Investigator Atopic Dermatitis Clinical Trials, Abbvie Project Period: 2018-current Phase 3, Randomized, Placebo control, Double Blind Study to evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis • Co Primary Investigator Clinical Trials, Astra Zeneca Project Period: 2020-current D3253C00001 study (MANDARA Study), Utilizing BVAS/VDI for Assessment of Eosinophilic Granulomatosis with Polyangiitis
Languages
- Turkish
Courses Taught
9/2019: Updates in Food Allergies. New Mexico Medical Society Annual Meeting. Albuquerque, NM. 9/2019: Immunodeficiency Foundation Education Meeting. Overview of Immune system. Albuquerque, NM. 4/2019: Food Allergies: Management in 2019. APP Regional Meeting, Ambulatory Providers Educational Series, GR18-ACP. Albuquerque, NM. 4/2019: American Lung Association, Regional Asthma Educators Course: Factors Contributing to Asthma Exacerbations. Albuquerque, NM.
Research and Scholarship
Uncontrolled Epstein-Barr Virus as an Atypical Presentation of Deficiency in ADA2 (DADA2). Brooks,...Dokmeci, Lakhani & Lucas.Journal of Clinical Immunology, 4 Jan 2021 Lentiviral gene therapy with low dose busulfan for infants with X-SCID: Novel gene therapy for X-SCID infants. Mamcarz,... Dokmeci, Puck, Cowan, Sorrentino. N Engl J Med. 2019 Apr 18;380 (16):1525-1534. doi: 10.1056/NEJMoa1815408 Dynamic re-immunization of off-treatment childhood cancer survivors: An implementation feasibility study. Han, Harmoney, Dokmeci , Torrez, Chavez, Cordova de Ortega , Kuttesch,Muller , Winter. PLoS One. 2018 Feb 1;13(2):e0191804. doi: 10.1371/journal.pone.0191804. eCollection 2018. Interim Results from a Phase I/II Clinical Gene Therapy Study for Newly Diagnosed Infants with X-Linked Severe Combined Immunodeficiency Using a Safety-Modified Lentiviral Vector and Targeted Reduced Exposure to Busulfan. Mamcarz, Zhou, .. Dokmeci, Puck, Cowan and Sorrentino. Blood Dec 2017 130:523. EBI-3 deficiency is Associated with diminished Th1 and increased Th2 mediated airway inflammation. Dokmeci E, Xu L, Robinson E, Golubets K, Bottomly K, Herrick C. Immunology 2011 Apr; 132(4):559-66. The immune system and atopic dermatitis. Dokmeci E, Herrick CA. Seminars in Cutaneous Medicine and Surgery 2008; 27(2):138-43